Drug intelligence / Profile preview

BIIB145

Development stage: Phase 1
Lead developer: Biogen
Modality: Small Molecules
Administration: Oral

Overview

**BIIB145** is an investigational small molecule developed by Biogen for the potential treatment of multiple sclerosis (MS). It is currently in early clinical development, with a Phase 1 study (NCT07225517) evaluating its safety, tolerability, pharmacokinetics, and food effect in healthy adult volunteers through single and multiple ascending oral doses.[3][4] The trial includes fasted and fed conditions, with no specific mechanism of action disclosed in available data, and it is positioned as a candidate prior to testing in MS patients.[3][4][7]

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on BIIB145.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIIB145.

Explore the full profile